- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of oxerutins.
Chronic venous insufficiency oedema: symptomatic relief
500mg twice daily.
Children under 18 years
First trimester of pregnancy
Precautions and Warnings
Second trimester of pregnancy
Third trimester of pregnancy
Advise ability to drive/operate machinery may be affected by side effects
Advise patient to consult physician if condition worsens / does not improve
Treatment of leg oedema due to hepatic, renal or cardiac disease should be directed to the underlying cause. Oxerutins is not indicated for these conditions.
Pregnancy and Lactation
Oxerutins is contraindicated in the first trimester and should be used with caution in the second and third trimesters of pregnancy.
Animal studies show no increase in teratogenic or other effects to the foetus if used in the recommended dosage during pregnancy.
Use oxerutins with caution in breastfeeding.
In animal studies traces of oxerutins and/or metabolites have been found in the breast milk but the levels are not considered to be of clinical relevance.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2016
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 10 August 2016.
Summary of Product Characteristics: Paroven capsules. Novartis Consumer Health. Revised July 2019.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 21 August 2019
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.